Naobios and Sumagen partner to develop HIV vaccine
Drug Discovery World
APRIL 15, 2024
Naobios has signed a partnership agreement with Sumagen, a Korean-Canadian biotechnology company developing an HIV-1 vaccine candidate, to manage the manufacturing process during its Phase II clinical trials. At the end of 2022, the World Health Organization (WHO) reported that approximately 39 million people were living with HIV.
Let's personalize your content